Building Immunity Building Trust

Vaccines for a Healthier World

WE INVENT FOR LIFE

“We are committed to improve global health by utilising the latest scientific research to tackle the world’s greatest health threats”

Fighting against chronic inflamatory diseases

“Building Immunity Building Trust: Vaccines for a Healthier World”

Changing the world is possible. We’ve done it before.

Our Vision

Revolutionizing healthcare through innovative screening, diagnostics, preventive immunotherapies, and scientific excellence, enabling early disease detection, personalized intervention, and healthier lives worldwide.

Mission

To push the boundaries of scientific discovery, transforming healthcare with cutting-edge innovations and empowering individuals with the tools and knowledge to take charge of their well-being, ultimately creating a future where preventable diseases are minimized, and health is personalized.

Precision Medicine Solutions
for a Healthier Tomorrow

Advanced Vaccine Solutions for a Healthier Tomorrow

KITS

Inflanova is a leader in groundbreaking diagnostic solutions, empowering healthcare professionals to deliver faster, more accurate diagnoses and personalized treatment plans for their patients.
Read More

Vaccines

Harnessing cutting-edge technology and extensive research, our Vaccine represents a paradigm shift in healthcare.
Read More

Screening Programme

Our solutions enable early and accurate disease detection, allowing for the development of customized treatment plans that address individual needs and optimize health outcomes.
Read More

What People Say

Dr. Shailesh Kumar Samal

Co-Founder and CEO, Inflanova AB

Dr. Shailesh Kumar Samal is a leading authority in immunotherapy and biotechnology, with dual Ph.D. degrees in Medical Sciences from Karolinska Institutet and Biochemistry from Maastricht University.

Dr. Shailesh Kumar Samal

Co-Founder and CEO, Inflanova AB

Dr. Shailesh Kumar Samal is a leading authority in immunotherapy and biotechnology, with dual Ph.D. degrees in Medical Sciences from Karolinska Institutet and Biochemistry from Maastricht University.

Dr. Shailesh Kumar Samal

Co-Founder and CEO, Inflanova AB

Dr. Shailesh Kumar Samal is a leading authority in immunotherapy and biotechnology, with dual Ph.D. degrees in Medical Sciences from Karolinska Institutet and Biochemistry from Maastricht University.

The Power of Our Progress

Patents
0 +
Publications
0 +
Collaborations
0 +

Building Immunity, Building Trust :
Vaccines for a Healthier World

Inflanova AB is a vaccine development company committed to addressing chronic inflammatory diseases and viral infections through innovative science. Founded by Dr. Shailesh Kumar Samal and Dr. Johan Frostegård, our mission is to transform healthcare with vaccines that go beyond conventional approaches, offering protection against both immediate and long-term health threats.

With a commitment to improving global health, Inflanova AB is at the forefront of vaccine innovation, working to reduce the burden of chronic inflammatory diseases and viral infections, and helping people live healthier, longer lives.

Building Immunity, Building Trust:
Vaccines for a Healthier World

Inflanova Medtech Pvt. Ltd is a vaccine development company committed to addressing chronic inflammatory diseases and viral infections through innovative science. Founded by Dr. Shailesh Kumar Samal and Dr. Johan Frostegård, our mission is to transform healthcare with vaccines that go beyond conventional approaches, offering protection against both immediate and long-term health threats.

With a commitment to improving global health, Inflanova Medtech Pvt. Ltd is at the forefront of vaccine innovation, working to reduce the burden of chronic inflammatory diseases and viral infections, and helping people live healthier, longer lives.

“Building Immunity,
Building Trust : Vaccines for a
Healthier World”

Live Your Life Now To Secure
Future Generations

Join us in our fight against diseases and create a healthier world

Our Blogs Service With Us.

Lorem Ipsum is simply dummy text of the printing.

Lorem Ipsum is simply dummy text of the printing and typesetting industry.

Lorem Ipsum is simply dummy text of the printing.

Lorem Ipsum is simply dummy text of the printing and typesetting industry.

Lorem Ipsum is simply dummy text of the printing.

Lorem Ipsum is simply dummy text of the printing and typesetting industry.

Lorem Ipsum is simply dummy text of the printing.

Lorem Ipsum is simply dummy text of the printing and typesetting industry.
Lorem ipsum dolor sit amet, consectetuer adipiscing elit.

Lorem ipsum dolor sit amet, consectetuer adipiscing elit.

Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor.

Lorem ipsum dolor sit amet, consectetuer adipiscing elit.

Lorem ipsum dolor sit amet, consectetuer adipiscing elit.

Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor.

Lorem ipsum dolor sit amet, consectetuer adipiscing elit.

Lorem ipsum dolor sit amet, consectetuer adipiscing elit.

Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor.

Lorem ipsum dolor sit amet, consectetuer adipiscing elit.

Lorem ipsum dolor sit amet, consectetuer adipiscing elit.

Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor.

Company Founder Details.

Dr. Shailesh Kumar Samal

Founder and CEO
Inflanova Medtech Pvt. Ltd

Dr. Shailesh Kumar Samal is an accomplished expert in immunotherapy and biotechnology, with dual Ph.D. degrees in Medical Sciences from Karolinska Institutet and Biochemistry from Maastricht University.

Prof. Johan Frostegård

Co-Founder
Inflanova Medtech Pvt. Ltd

Prof. Johan Frostegård, a distinguished researcher and physician, leads the Unit of Immunology and Chronic Disease at Karolinska Institutet. His research focuses on the immune system’s role in cardiovascular diseases.

The Power of Our Team

Rabi Narayan Bastia

Director

Inflanova Medtech Pvt. Ltd

Dr_SantoshKumarMallik

Dr. Santosh Kumar Mallik

Chief Capacity Building Officer and Director

Inflanova Medtech Pvt. Ltd

Alisha Dash

Director - Operation

Inflanova Medtech Pvt. Ltd

Dr. Sandeep Keshavan

Chief Scientific Officer

Inflanova Medtech Pvt. Ltd

Corporate Office

Plot No- 132A, Sector-A, Mancheswar I.E, Rasulgarh, Bhubaneswar, Khorda-751010

Swedish Office

Karlbergsvägen 40 lgh 1401, 113 27 Stockholm
Scroll to Top

KITS

CardioDefine™ 

Engineering the Future of Preventive Cardiovascular Diagnostics

Cardio Define represents Inflanova’s vision for the next generation of immune biomarker-based diagnostics. Powered by our proprietary Anti-PC platform, we are developing technologies designed to transform how chronic inflammatory diseases are identified, understood, and managed, beginning with cardiovascular disease.

From precision diagnostics to population-scale screening, CardioDefine™ reflects our commitment to enabling a future where disease risk can be recognized earlier and prevention becomes more personalized.

Key Benefits:

  • Early risk detection and screening
  • ⁠Inflammation-focused health assessment
  • ⁠Support for personalized treatment strategies
  • Improved preventive healthcare outcomes

VetDefine™ 

Precision Diagnostics for the Next Era of Veterinary Medicine

VetDefine™ is Inflanova’s emerging veterinary diagnostics platform focused on bringing innovative biomarker science to companion animal healthcare. By exploring novel approaches to inflammation-based diagnostics, we aim to support veterinarians with tools designed for earlier health assessment and more informed clinical care.

Key Benefits:

  • Early disease detection in pets
  • ⁠Enhanced veterinary decision-making
  • ⁠Improved monitoring and preventive care
  • Better health outcomes for companion animals

Vaccines

Engineering the Future of Preventive Immunology

Inflanova is pioneering a first-in-class Anti-Phosphorylcholine (Anti-PC) vaccine platform designed to harness the immune system against chronic inflammation. By targeting one oInflanova’smental biological mechanisms underlying cardiovascular disease and other inflammation-driven conditions, we are advancing a new paradigm in preventive medicine.

CardioShield™

Protecting cardiovascular health through next-generation immunology.

CardioShield™ is Inflanova’s flagship vaccimmunization under development for cardiovascular disease prevention. Built on our proprietary Anti-PC technology, it is being designed to stimulate protective immune responses against chronic inflammation, supporting the future of precision preventive medicine.

PetShield™

Extending preventive immunology to the futuimmunizationion animal health.

Immunization PetsShield™ is Inflanova’s veterinary vaccine platform under development, applying our Anti-PC technology to companion animal health. The platform aims to explore innovative immunization strategies for inflammation-associated diseases, advancing the future of preventive veterinary care.

Screening Program

Many chronic diseases develop silently over years before symptoms become visible. By the time clinical signs appear, significant damage may already have occurred. Inflanova’s population screening initiatives are designed to identify individuals at risk earlier, enabling timely intervention and improving long-term health outcomes.

Leveraging advanced biomarker-based screening technologies, scientific expertise, and data-driven healthcare approaches, we support large-scale screening programs aimed at detecting risks associated with cardiovascular diseases, chronic kidney disease, diabetes, and other chronic inflammatory conditions.

Our approach helps governments, healthcare providers, employers, and community organizations move from reactive treatment to proactive prevention. Through early risk identification and personalized follow-up strategies, population screening can reduce disease burden, improve quality of life, and lower healthcare costs.

At Inflanova, we envision a future where preventive screening becomes an integral part of public health, empowering populations to take charge of their health and enabling healthcare systems to intervene before disease progresses.

Dr. Shailesh Kumar Samal

Founder and CEO
Inflanova Medtech Pvt. Ltd

Dr. Shailesh Kumar Samal is an accomplished expert in immunotherapy and biotechnology, with dual Ph.D. degrees in Medical Sciences from Karolinska Institutet and Biochemistry from Maastricht University. As a serial entrepreneur, he has founded and led several biotech companies, including Inflanova Medtech Pvt. Ltd. Dr. Samal has collaborated with Nobel laureates worldwide and is a nominated member of Sigma Xi, The Scientific Research Honor Society, known for its prestigious membership that includes 200 Nobel laureates. Sigma Xi, founded in 1886, honors excellence in scientific research and fosters collaboration among scientists and engineers. Dr. Samal also serves as an adjunct professor at IIT Ropar, where he is the youngest professor across all IITs. His pioneering work in developing vaccines and diagnostics for chronic inflammatory conditions reflects his deep commitment to advancing science and education.

Prof. Johan Frostegård

Co-Founder
Inflanova Medtech Pvt. Ltd

Prof. Johan Frostegård, a distinguished researcher and physician, leads the Unit of Immunology and Chronic Disease at Karolinska Institutet. His research focuses on the immune system’s role in cardiovascular diseases. Frostegård has co-founded multiple biotech startups, including Inflanova Medtech Pvt. Ltd, and serves as an advisor to various companies. With a background in economics and medicine, he also writes novels and popular science books, offering insights on humanities and societal issues. His multifaceted contributions continue to influence both science and literature.

Rabi Narayan Bastia

Director
Inflanova Medtech Pvt. Ltd

Rabi Narayan Bastia is a seasoned business leader and Director of Inflanova Medtech Pvt. Ltd., recognized for his strategic vision and commitment to innovation in the healthcare and medical technology sector. With extensive experience in business leadership, operations, and organizational growth, he has played a pivotal role in driving the company’s expansion and fostering a culture of excellence. His forward-thinking approach, strong industry expertise, and dedication to delivering impactful healthcare solutions continue to strengthen Inflanova Medtech’s position in the industry. Through his leadership and commitment to quality, he remains instrumental in shaping the organization’s long-term success.

Dr_SantoshKumarMallik

Dr. Santosh Kumar Mallik

Chief Capacity Building Officer and Director
Inflanova Medtech Pvt. Ltd

With over 30 years of diverse business and HR leadership experience, Dr. Santosh Kumar Mallick brings a strong execution-driven approach to Inflanova’s growing operations. He combines deep expertise in organizational growth, people management, and HR product development to support Inflanova’s mission of advancing scientific innovation. His consultative leadership style, ability to manage complex administrative functions, and focus on aligning people strategies with business objectives make him a key pillar in driving operational excellence as Inflanova expands its global biotech and diagnostics footprint.

Alisha Dash

Director - Operation
Inflanova Medtech Pvt. Ltd

Alisha Dash is the Director – Operation at Inflanova, with a strong background in biotechnology. She leads pioneering research in vaccine development and diagnostics, focusing on chronic inflammatory conditions. With numerous scientific publications and patents to her name, Alisha is renowned for her keen research mind and deep expertise in medical sciences. Alisha’s dedication to scientific excellence and her collaborative spirit drive Inflanova’s mission to create impactful solutions for global health challenges.

Dr Sandeep Keshavan

Chief Scientific Officer
Inflanova Medtech Pvt. Ltd

As the Chief Scientific Officer of Inflanova Medtech Pvt.Ltd, Dr. Sandeep Keshavan brings over a decade of expertise in biotechnology to drive the company’s mission forward. Dr. Keshavan received his Ph.D. from the Istituto Italiano di Tecnologia and has dedicated his career to advancing healthcare through pioneering research. He has led numerous transformative projects in regenerative medicine, nanomedicine, and cancer therapy. His contributions, from deciphering immune cell responses to developing advanced 3D lung models, aim to unravel the intricate mechanisms underlying innovative treatments for common pathological conditions. With a track record of success in project management across various institutions, including the Karolinska Institutet and the Adolphe Merkle Institute, Dr. Keshavan’s strategic vision and dedication to scientific advancement are evident. His efforts position Inflanova AB at the forefront of healthcare innovation, shaping a future where proactive, personalized healthcare is the norm.

Dr. Mrutyunjay Suar

Board Member and Scientific Advisor.

Mr. Himanshu Nayak

Product Owner at Ericsson, Sweden

Mr. Riken Gala

Serial Entrepreneur, Director, Avior Lifesciences.

Dr. Sachin Kote

Group Leader, Clinical Peptidomics Group, International Centre for Cancer Vaccine Science, University of Gdańsk, Poland

Dr. Raghavendra GoudVaggu

Exec-Director PharmNXT, IISc, IIM, ISB

Prof. Rajeev Ahuja

Director, IIT Ropar

Dr. Mona Duggal

Director, ICMR- National Institute for Research in Digital Health and Data Sciences, New Delhi

Dr. Nobuyo Maeda

Robert H Wagner Distinguished Professor, Department of Pathology and Laboratory Medicine, University of North Carolina – Chapel Hill, USA

Prof Karl Andersson

Professor and Head of Subject, Dean, Computer Science, Department of Computer Science, Electrical and Space Engineering, Lulea University of Technology, Sweden

Prof Karl Andersson

Director, Cardiovascular Research Institute (CARIM), Maastricht University, Netherlands

Prof Leon Schurgers

CARIM School for Cardiovascular Diseases, Maastricht University

Dr. Varindar Garg

OSD to President PGIMER- Union Health Minister

Mr. Prem Satpathy

Board Member and Business Advisor, Deep Tech Alchemist.